US 12,134,610 B2
Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
Jian Zhao, San Diego, CA (US); Yunfei Zhu, San Diego, CA (US); and Mi Chen, San Diego, CA (US)
Assigned to CRINETICS PHARMACEUTICALS, INC., San Diego, CA (US)
Filed by Crinetics Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Feb. 6, 2024, as Appl. No. 18/434,159.
Application 18/434,159 is a continuation of application No. 18/535,503, filed on Dec. 11, 2023.
Claims priority of provisional application 63/597,871, filed on Nov. 10, 2023.
Claims priority of provisional application 63/387,235, filed on Dec. 13, 2022.
Prior Publication US 2024/0254105 A1, Aug. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61P 35/00 (2006.01); C07D 405/14 (2006.01); C07D 491/22 (2006.01); C07D 498/04 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/00 (2018.01); C07D 405/14 (2013.01); C07D 491/22 (2013.01); C07D 498/04 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A compound that has the structure of Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
A is —N(H)— or —O—;
Ra is hydrogen or C1-C6alkyl;
R2 is hydrogen or C1-C6alkyl;
R6 is chloro or —C(═O)NH2;
L is -L1-L2-;
L1 is an optional spacer; and
L2 is an optional linker;
wherein at least one of L1 or L2 is present; and
Rd is a payload moiety comprising a chemotherapeutic agent.